Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6228368,retention times,"A good separation of zimelidine and norzimelidine was obtained following derivatisation of norzimelidine with heptafluorobutyric anhydride, the retention times being 6.16 and 10.35 minutes, respectively.",Pharmacokinetic study of zimelidine using a new GLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),min,6.16,10294,DB00408,Loxapine
,6228368,retention times,"A good separation of zimelidine and norzimelidine was obtained following derivatisation of norzimelidine with heptafluorobutyric anhydride, the retention times being 6.16 and 10.35 minutes, respectively.",Pharmacokinetic study of zimelidine using a new GLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),min,10.35,10295,DB00408,Loxapine
,6228368,sensitivity,The sensitivity of the method is 5 ng/ml for zimelidine and norzimelidine.,Pharmacokinetic study of zimelidine using a new GLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),[ng] / [ml],5,10296,DB00408,Loxapine
,6228368,peak plasma concentration,"Zimelidine was rapidly absorbed, giving a mean peak plasma concentration of 103.9 +/- 34.8 ng/ml.",Pharmacokinetic study of zimelidine using a new GLC method. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),[ng] / [ml],103.9,10297,DB00408,Loxapine
,6228368,plasma elimination half-life,The mean plasma elimination half-life was 8.4 +/- 2.0 hours for zimelidine and 19.4 +/- 3.6 hours for norzimelidine.,Pharmacokinetic study of zimelidine using a new GLC method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),h,8.4,10298,DB00408,Loxapine
,6228368,plasma elimination half-life,The mean plasma elimination half-life was 8.4 +/- 2.0 hours for zimelidine and 19.4 +/- 3.6 hours for norzimelidine.,Pharmacokinetic study of zimelidine using a new GLC method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6228368/),h,19.4,10299,DB00408,Loxapine
>,28647110,half-life,"Plasmatic drug concentrations showed a supratherapeutic concentration of loxapine with a very low 8-hydroxyloxapine/loxapine ratio (range from 0.32 to 0.66, normal value>2 for 100mg) and a very long elimination half-life of loxapine (half-life>140h, normal value from 1 to 4hours).",Success of tardive electroconvulsive therapy sessions after loxapine-induced malignant syndrome in the context of very poor metabolisation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28647110/),h,140,35457,DB00408,Loxapine
,26445139,Cmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445139/),[ng] / [ml],177,49888,DB00408,Loxapine
,26445139,tmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445139/),min,2,49889,DB00408,Loxapine
,26445139,tmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26445139/),h,2.03,49890,DB00408,Loxapine
,25808074,Tmax,"Following inhalation, the median Tmax was 2 minutes, and concentrations declined to about half Cmax approximately 5 minutes later across the 3 dose levels.","Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808074/),min,2,74902,DB00408,Loxapine
,19915181,t(max),"Following inhalation, the t(max) median (25%, 75%) was 2 (1, 3) minutes.",Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19915181/),min,2,87833,DB00408,Loxapine
,6707884,Recoveries,"Recoveries of III, I, and II were 95, 85, and 79%, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),%,95,112365,DB00408,Loxapine
,6707884,Recoveries,"Recoveries of III, I, and II were 95, 85, and 79%, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),%,85,112366,DB00408,Loxapine
,6707884,Recoveries,"Recoveries of III, I, and II were 95, 85, and 79%, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),%,79,112367,DB00408,Loxapine
,6707884,areas under the curve,"The areas under the curve for these two patients were 275 and 273 ng.h/mL, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),[h·ng] / [ml],275,112368,DB00408,Loxapine
,6707884,areas under the curve,"The areas under the curve for these two patients were 275 and 273 ng.h/mL, respectively.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),[h·ng] / [ml],273,112369,DB00408,Loxapine
,6707884,apparent volumes of distribution,"The apparent volumes of distribution were 493.6 and 288.6 L, and the elimination half-lives were 4.70 and 2.73 h.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),l,493.6,112370,DB00408,Loxapine
,6707884,apparent volumes of distribution,"The apparent volumes of distribution were 493.6 and 288.6 L, and the elimination half-lives were 4.70 and 2.73 h.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),l,288.6,112371,DB00408,Loxapine
,6707884,elimination half-lives,"The apparent volumes of distribution were 493.6 and 288.6 L, and the elimination half-lives were 4.70 and 2.73 h.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),h,4.70,112372,DB00408,Loxapine
,6707884,elimination half-lives,"The apparent volumes of distribution were 493.6 and 288.6 L, and the elimination half-lives were 4.70 and 2.73 h.",Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707884/),h,2.73,112373,DB00408,Loxapine
∼13,28510296,terminal elimination half-life,Loxapine terminal elimination half-life was ∼13 to 17 hours.,Pharmacokinetics and Safety of Single-Dose Inhaled Loxapine in Children and Adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510296/),h,17,147305,DB00408,Loxapine
,27121764,time to maximum plasma concentration,"Inhaled loxapine is rapidly absorbed with intravenous-like pharmacokinetics, with a time to maximum plasma concentration of 2 minutes and a plasma half-life of approximately 6 hours.",Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121764/),min,2,149191,DB00408,Loxapine
,27121764,plasma half-life,"Inhaled loxapine is rapidly absorbed with intravenous-like pharmacokinetics, with a time to maximum plasma concentration of 2 minutes and a plasma half-life of approximately 6 hours.",Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121764/),h,6,149192,DB00408,Loxapine
,24554118,bioavailabilities,"Nasal bioavailabilities in long-term anesthetized model (tacrine 83%, loxapine 97%) were much higher than that in conscious model (tacrine 10%, loxapine 46%).","Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554118/),%,83,180839,DB00408,Loxapine
,24554118,bioavailabilities,"Nasal bioavailabilities in long-term anesthetized model (tacrine 83%, loxapine 97%) were much higher than that in conscious model (tacrine 10%, loxapine 46%).","Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554118/),%,97,180840,DB00408,Loxapine
,24554118,bioavailabilities,"Nasal bioavailabilities in long-term anesthetized model (tacrine 83%, loxapine 97%) were much higher than that in conscious model (tacrine 10%, loxapine 46%).","Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554118/),%,10,180841,DB00408,Loxapine
,24554118,bioavailabilities,"Nasal bioavailabilities in long-term anesthetized model (tacrine 83%, loxapine 97%) were much higher than that in conscious model (tacrine 10%, loxapine 46%).","Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554118/),%,46,180842,DB00408,Loxapine
,32879225,activation energy (Ea),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[kj] / [mol],88.70,195214,DB00408,Loxapine
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],-,195215,DB00408,Loxapine
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],80.73,195216,DB00408,Loxapine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,3,195217,DB00408,Loxapine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,30,195218,DB00408,Loxapine
,24375070,Tmax,Plasma concentrations of loxapine increased with a median Tmax of 1 minute and a mean Cmax of 312 ng/mL.,Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375070/),min,1,215120,DB00408,Loxapine
,24375070,Cmax,Plasma concentrations of loxapine increased with a median Tmax of 1 minute and a mean Cmax of 312 ng/mL.,Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375070/),[ng] / [ml],312,215121,DB00408,Loxapine
,24375070,terminal half-life,"After an initial rapid distribution phase, plasma concentrations of loxapine declined with a terminal half-life of 8 hours.",Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375070/),h,8,215122,DB00408,Loxapine
,24375070,terminal half-life,Exposure to the active metabolite 7-OH-loxapine was 15% of the parent compound based on mean AUCinf and its terminal half-life was 12 hours.,Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24375070/),h,12,215123,DB00408,Loxapine
exceeded,26501204,ΔΔTcI,"Post loxapine dosing, no ΔΔTcI 95% upper CI exceeded 10 msec; the largest was 6.31 msec 5 minutes post dose 2.","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),ms,10,225454,DB00408,Loxapine
,26501204,ΔΔTcI,"Post loxapine dosing, no ΔΔTcI 95% upper CI exceeded 10 msec; the largest was 6.31 msec 5 minutes post dose 2.","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),ms,6.31,225455,DB00408,Loxapine
,26501204,Cmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),[ng] / [ml],177,225456,DB00408,Loxapine
,26501204,tmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),min,2,225457,DB00408,Loxapine
,26501204,tmax,"Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1).","A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26501204/),h,2.03,225458,DB00408,Loxapine
,3997304,maximum levels,Amoxapine reached maximum levels of 67.4 +/- 35.8 ng/ml between 1 and 2 h after administration.,Pharmacokinetics of amoxapine and its active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997304/),[ng] / [ml],67.4,233865,DB00408,Loxapine
,3997304,elimination half-life,The mean elimination half-life was 9.8 +/- 2.6 h and the estimated first-pass loss ranged between 0.18 and 0.54.,Pharmacokinetics of amoxapine and its active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997304/),h,9.8,233866,DB00408,Loxapine
,3997304,first-pass loss,The mean elimination half-life was 9.8 +/- 2.6 h and the estimated first-pass loss ranged between 0.18 and 0.54.,Pharmacokinetics of amoxapine and its active metabolites. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997304/),,0.18 and 0.54,233867,DB00408,Loxapine
,3997304,elimination half-lives,The mean elimination half-lives were 30.8 and 5.1 h for 8-hydroxyamoxapine and 7-hydroxyamoxapine respectively.,Pharmacokinetics of amoxapine and its active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997304/),h,30.8,233868,DB00408,Loxapine
,3997304,elimination half-lives,The mean elimination half-lives were 30.8 and 5.1 h for 8-hydroxyamoxapine and 7-hydroxyamoxapine respectively.,Pharmacokinetics of amoxapine and its active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997304/),h,5.1,233869,DB00408,Loxapine
≤,23739987,tmax,"Intranasally administered loxapine was efficiently absorbed into systemic circulation followed by entering brain, with tmax ≤15 min in all brain regions.",Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in PK/PD of intranasal CNS drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739987/),min,15,236624,DB00408,Loxapine
,10479356,half-life,Plasma levels of the prodrugs fell below the limit of detection 5 min after iv infusion with an approximate half-life of 1 min.,A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10479356/),min,1,242594,DB00408,Loxapine
,24937085,Tmax,"The median loxapine Tmax was 1.88 and 1.01 minutes for nonsmokers and smokers, respectively.",Effect of smoking on the pharmacokinetics of inhaled loxapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937085/),min,1.88,244221,DB00408,Loxapine
,24937085,Tmax,"The median loxapine Tmax was 1.88 and 1.01 minutes for nonsmokers and smokers, respectively.",Effect of smoking on the pharmacokinetics of inhaled loxapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937085/),min,1.01,244222,DB00408,Loxapine
,24937085,terminal half-life,A slight decrease in the observed mean terminal half-life values was observed for smokers (6.52 hours for smokers and 7.30 hours for nonsmokers).,Effect of smoking on the pharmacokinetics of inhaled loxapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937085/),h,6.52,244223,DB00408,Loxapine
,24937085,terminal half-life,A slight decrease in the observed mean terminal half-life values was observed for smokers (6.52 hours for smokers and 7.30 hours for nonsmokers).,Effect of smoking on the pharmacokinetics of inhaled loxapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937085/),h,7.30,244224,DB00408,Loxapine
